Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

BMS-986458 a Potential First-in-Class, Highly Selective, Potent and Well Tolerated BCL6 Ligand Directed Degrader (LDD) Demonstrates Multi-Modal Anti-Tumor Efficacy for the Treatment of B-Cell Non-Hodgkin's Lymphoma

Blood (2024) 144 (Supplement 1): 957.

https://doi.org/10.1182/blood-2024-210951

Published: 2024

Journal Articles

Longer Follow-up of Golcadomide (GOLCA), a Cereblon E3 Ligase Modulator (CELMoD™) Agent ± Rituximab (RTX), in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Jean-Marie Michot, Franck Morschhauser, Silvia Ferrari, Judit Mészáros Jørgensen, Loretta Nastoupil, Emmanuel Bachy, Michael Pourdehnad, Akshay Sudhindra, Alev Akyol, Bérengère de Moucheron, Soraya Carrancio, Jessica Voetsch, Xirong Zheng, Julio C. Chavez

Blood (2024) 144 (Supplement 1): 869.

https://doi.org/10.1182/blood-2024-203163

Published: 2024

Journal Articles

Development of a ZBTB7A and Wiz Dual Degrading, HbF-Activating CELMoD™ for the Treatment of Sickle Cell Disease

Blood (2024) 144 (Supplement 1): 169.

https://doi.org/10.1182/blood-2024-203653

Published: 2024

Journal Articles

Synergistic Activity of BMS-986397, a First-in-Class a Cereblon (CRBN) E3 Ligase Modulator (CELMoD) Targeting Casein Kinase 1α (CK1α), in Combination with Venetoclax and/or Azacitidine in Preclinical Models of Acute Myeloid Leukemia (AML)

Carmen Jimenez, Jose Francisco Lopez, Estela Garcia, Laura Diaz Regalado, Alejandro Panjkovich, Sophie Peng, Rama Krishna Narla, Noelia Purroy, Mark Rolfe, Daniel W. Pierce, Soraya Carrancio

Blood (2024) 144 (Supplement 1): 1395.

https://doi.org/10.1182/blood-2024-210023

Published: 2024

Journal Articles

BMS-986397, a First-in-Class Molecular Glue Degrader of Casein Kinase 1α (CK1α) for the Treatment of Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS) Harboring Functional TP53

Carmen Jimenez, Sophie Peng, Rama Krishna Narla, Joshua Baughman, Scott Wood, Jean Lu, Noelia Purroy, Gina Yanochko, Mark Nagy, Gang Lu, Mark Rolfe, Daniel W. Pierce, Soraya Carrancio

Blood (2024) 144 (Supplement 1): 4142.

https://doi.org/10.1182/blood-2024-209924

Published: 2024

Journal Articles

Cell-Intrinsic and Immune-Mediated Effects in Lymphoma Patients Treated with Golcadomide and Associations with Treatment Outcome

Soraya Carrancio, Jessica Voetsch, Alberto Risueño, Carla Guarinos, Siddhesh Kulkarni, Mandeep Takhar, Matthew E. Stokes, Bérengère de Moucheron, Laura Furman, Julio C. Chavez, Jean-Marie Michot, Loretta Nastoupil, Daniel W. Pierce, Danielle Greenawalt, Michael Pourdehnad

Blood (2024) 144 (Supplement 1): 3104.

https://doi.org/10.1182/blood-2024-203139

Published: 2024

Journal Articles

Efficacy and Safety of Golcadomide, a Novel Cereblon E3 Ligase Modulator (CELMoD) Agent, Combined with Rituximab in a Phase 1/2 Open-Label Study of Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Julio C. Chavez, Loretta J. Nastoupil, Franck Morschhauser, Guillaume Cartron, Judit Mészáros Joergensen, Emmanuel Bachy, Pierre Bories, Victoria Campbell, Bijou Fontanet, Poliana P. Patah, Bérengère de Moucheron, Soraya Carrancio, Xirong Zheng, Chaoqun Mei, Michael Pourdehnad, Jean-Marie Michot

Blood (2023) 142 (Supplement 1): 4496.

https://doi.org/10.1182/blood-2023-188771

Published: 2023

Journal Articles

Mezigdomide (CC-92480), a Novel Cereblon E3 Ligase Modulator, Induces Vulnerability of Multiple Myeloma Cells to T-Cell-Mediated Killing

Bonny Gaffney, Yu Shi, Petrus de Jong, Manuel Sanchez, Celia Fontanillo, Antonia Lopez-Girona, Isaac W. Boss, Antonina Kurtova, Soraya Carrancio, Lilly Wong, Daniel W. Pierce

Blood (2022) 140 (Supplement 1): 7108–7109.

https://doi.org/10.1182/blood-2022-157939

Published: 2022

Journal Articles

Association of Immune Dynamics and Treatment Outcome in Patients (pts) with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL) Treated with the Novel Cereblon (CRBN) E3 Ligase Modulator (CELMoD) Agent CC-99282

Soraya Carrancio, Wen-Chi Chou, Alberto Risueño, Carla Guarinos, Gonzalo Lopez, Jean-Marie Michot, Loretta J. Nastoupil, Julio Chavez, Cecilia Carpio, Silvia Ferrari, Tatyana A. Feldman, Daniel Morillo Giles, Antonio Pinto, Danielle Greenawalt, Daniel W. Pierce, Michael Pourdehnad

Blood (2022) 140 (Supplement 1): 6455–6457.

https://doi.org/10.1182/blood-2022-159585

Published: 2022

Journal Articles

Clinical Activity of CC-99282, a Novel, Oral Small Molecule Cereblon E3 Ligase Modulator (CELMoD) Agent, in Patients (Pts) with Relapsed or Refractory Non-Hodgkin Lymphoma (R/R NHL) - First Results from a Phase 1, Open-Label Study

Jean-Marie Michot, Julio C. Chavez, Cecilia Carpio, Silvia Ferrari, Tatyana A. Feldman, Daniel Morillo, John Kuruvilla, Antonio Pinto, Vincent Ribrag, Emmanuel Bachy, Tonia J Buchholz, Soraya Carrancio, Carla Guarinos, Fan Wu, Shaoyi Li, Poliana Patah, Michael Pourdehnad, Loretta Nastoupil

Blood (2021) 138 (Supplement 1): 3574.

https://doi.org/10.1182/blood-2021-147333

Published: 2021

Journal Articles

Synergistic Combination Activity of the Novel GSPT1 Degrader CC-90009 in Acute Myeloid Leukemia Models

Daniel W. Pierce, Tsun-Wen Sheena Yao, Emily Pace, Hongbin Wang, Pierre Flandin-Blety, Alicia Benitez, Carla Guarinos, Matthew Hoffmann, Soraya Carrancio, Jinhong Fan, Michael Pourdehnad

Blood (2021) 138 (Supplement 1): 3330.

https://doi.org/10.1182/blood-2021-147160

Published: 2021

Journal Articles

CC-99282 is a Novel Cereblon (CRBN) E3 Ligase Modulator (CELMoD) Agent with Enhanced Tumoricidal Activity in Preclinical Models of Lymphoma

Soraya Carrancio, Lynda Groocock, Preethi Janardhanan, Diana Jankeel, Ryan Galasso, Carla Guarinos, Rama K. Narla, Matthew Groza, Jim Leisten, Daniel W. Pierce, Mark Rolfe, Antonia Lopez-Girona

Blood (2021) 138 (Supplement 1): 1200.

https://doi.org/10.1182/blood-2021-148068

Published: 2021

Journal Articles

Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier

Blood (2020) 135 (13): 996–1007.

https://doi.org/10.1182/blood.2019002395

Published: 2020

Includes: Supplemental data

Journal Articles

CC-122 Dosing on a Novel Intermittent Schedule Mitigates Neutropenia and Maintains Clinical Activity in Subjects with Relapsed or Refractory Diffuse Large B Cell Lymphoma

Cecilia Carpio, MD, Loïc Ysebaert, MDPhD, Raúl Cordoba, MD, Armando Santoro, MD, José Antonio López-Martín, MD, Juan Manuel Sancho, MD PhD, Carlos Panizo, PhD, Mecide Meric Gharibo, MD, Drew W Rasco, MD, Anne-Marie Stoppa, MD, Sylvia Damian, MD, Xin Wei, Patrick Hagner, PhD, Kristen Hege, Soraya Carrancio, PhD, Anita K. Gandhi, PhD, Michael Pourdehnad, MD, Vincent Ribrag, MD

Blood (2015) 126 (23): 1494.

https://doi.org/10.1182/blood.V126.23.1494.1494

Published: 2015

Journal Articles

Sotatercept Promotes Differentiation and Survival Of Erythroid Progenitors By Blocking Inhibitory Effects Of TGFβ Superfamily Members

Soraya Carrancio, PhD, Jennifer A. Markovics, PhD, Piu Wong, PhD, Carla Heise, PhD, Tom O. Daniel, MD, PhD, Rajesh Chopra, MD, Victoria Sung, PhD

Blood (2013) 122 (21): 944.

https://doi.org/10.1182/blood.V122.21.944.944

Published: 2013

Journal Articles

Sotatercept, an Activin Receptor IIa Ligand Trap, Acts Through Bone Marrow Accessory Cells to Promote Late-Stage Erythropoiesis and a Rapid Induction of Red Blood Cell Number and Hemoglobin

Soraya Carrancio, PhD, Jennifer A Markovics, PhD, Piu Wong, PhD, Jim Leisten, Matthew C Groza, Heather K Raymon, Carla Heise, PhD, Rajesh Chopra, MD, PhD, Tom O Daniel, MD, PhD, Victoria Sung, PhD

Blood (2012) 120 (21): 372.

https://doi.org/10.1182/blood.V120.21.372.372

Published: 2012

Journal Articles

Lenalidomide Differentially Modifies the Genomic Profile and miRNA Expression of Mesenchymal Stromal Cells From Patients with 5q- Syndrome,

Sandra Muntión, PhD, Carlos Santamaría, PhD, Beatriz Roson, Carlos Romo, Olga López-Villar, MD, PhD, Soraya Carrancio, PhD, Fermin M. Sanchez-Guijo, MD, PhD, María Diez-Campelo, MD, PhD, Maria-Eugenia Sarasquete, PhD, Javier de las Rivas, PhD, Marcos González, MD, Jesus F. San Miguel, MD, PhD, Maria-Consuelo del Cañizo, MD, PhD

Blood (2011) 118 (21): 3810.

https://doi.org/10.1182/blood.V118.21.3810.3810

Published: 2011

Journal Articles

Effect of Demethylating Agents (5-Azacytidine/5-AzaC) On the Immune Response

Silvia Gutiérrez Cosío, Esteban Ballestar, Carlos Santamaría, Belén Blanco, Luis Ignacio Sánchez Abarca, Teresa Caballero Velázquez, Carmen Herrero Sánchez, Soraya Carrancio, Laura Ciudad, Consuelo Cañizo, Jesus F San Miguel, Jose Antonio Pérez Simón

Blood (2010) 116 (21): 2771.

https://doi.org/10.1182/blood.V116.21.2771.2771

Published: 2010

Journal Articles

Effect of 5-Azacytidine (5-AzaC) In the Expression of PRAME In Acute Myeloid Leukemia (AML)

Silvia Gutiérrez Cosío, Esteban Ballestar, Carlos Santamaría, Belen Blanco, Luis Ignacio Sánchez Abarca, Teresa Caballero Velázquez, Carmen Herrero Sánchez, Soraya Carrancio, Laura Ciudad, Consuelo Cañizo, Jesus F San Miguel, Jose Antonio Pérez Simón

Blood (2010) 116 (21): 3615.

https://doi.org/10.1182/blood.V116.21.3615.3615

Published: 2010

Journal Articles

Mesenchymal Stromal Cells From Myelodysplastic Syndrome Patients Show Lower DICER1 and DROSHA Expression, as Well as Decreased Mir-155 and Mir-181a MicroRNA Expression, When Compared with Healthy Controls

Carlos Santamaría, Olga López-VIllar, Sandra Muntión, Belén Blanco, Soraya Carrancio, Fermin M. Sanchez-Guijo, María Diez-Campelo, Stela Álvarez-Fernández, María E. Sarasquete, Marcos González, Jesús F. San Miguel, María C. Del Cañizo

Blood (2010) 116 (21): 397.

https://doi.org/10.1182/blood.V116.21.397.397

Published: 2010

NARROW

BMS-986458 a Potential First-in-Class, Highly Selective, Potent and Well Tolerated BCL6 Ligand Directed Degrader (LDD) Demonstrates Multi-Modal Anti-Tumor Efficacy for the Treatment of B-Cell Non-Hodgkin's Lymphoma

Longer Follow-up of Golcadomide (GOLCA), a Cereblon E3 Ligase Modulator (CELMoD™) Agent ± Rituximab (RTX), in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Development of a ZBTB7A and Wiz Dual Degrading, HbF-Activating CELMoD™ for the Treatment of Sickle Cell Disease

Synergistic Activity of BMS-986397, a First-in-Class a Cereblon (CRBN) E3 Ligase Modulator (CELMoD) Targeting Casein Kinase 1α (CK1α), in Combination with Venetoclax and/or Azacitidine in Preclinical Models of Acute Myeloid Leukemia (AML)

BMS-986397, a First-in-Class Molecular Glue Degrader of Casein Kinase 1α (CK1α) for the Treatment of Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS) Harboring Functional TP53

Cell-Intrinsic and Immune-Mediated Effects in Lymphoma Patients Treated with Golcadomide and Associations with Treatment Outcome

Efficacy and Safety of Golcadomide, a Novel Cereblon E3 Ligase Modulator (CELMoD) Agent, Combined with Rituximab in a Phase 1/2 Open-Label Study of Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Mezigdomide (CC-92480), a Novel Cereblon E3 Ligase Modulator, Induces Vulnerability of Multiple Myeloma Cells to T-Cell-Mediated Killing

Association of Immune Dynamics and Treatment Outcome in Patients (pts) with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL) Treated with the Novel Cereblon (CRBN) E3 Ligase Modulator (CELMoD) Agent CC-99282

Clinical Activity of CC-99282, a Novel, Oral Small Molecule Cereblon E3 Ligase Modulator (CELMoD) Agent, in Patients (Pts) with Relapsed or Refractory Non-Hodgkin Lymphoma (R/R NHL) - First Results from a Phase 1, Open-Label Study

Synergistic Combination Activity of the Novel GSPT1 Degrader CC-90009 in Acute Myeloid Leukemia Models

CC-99282 is a Novel Cereblon (CRBN) E3 Ligase Modulator (CELMoD) Agent with Enhanced Tumoricidal Activity in Preclinical Models of Lymphoma

Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier

CC-122 Dosing on a Novel Intermittent Schedule Mitigates Neutropenia and Maintains Clinical Activity in Subjects with Relapsed or Refractory Diffuse Large B Cell Lymphoma

Sotatercept Promotes Differentiation and Survival Of Erythroid Progenitors By Blocking Inhibitory Effects Of TGFβ Superfamily Members

Sotatercept, an Activin Receptor IIa Ligand Trap, Acts Through Bone Marrow Accessory Cells to Promote Late-Stage Erythropoiesis and a Rapid Induction of Red Blood Cell Number and Hemoglobin

Lenalidomide Differentially Modifies the Genomic Profile and miRNA Expression of Mesenchymal Stromal Cells From Patients with 5q- Syndrome,

Effect of Demethylating Agents (5-Azacytidine/5-AzaC) On the Immune Response

Effect of 5-Azacytidine (5-AzaC) In the Expression of PRAME In Acute Myeloid Leukemia (AML)

Mesenchymal Stromal Cells From Myelodysplastic Syndrome Patients Show Lower DICER1 and DROSHA Expression, as Well as Decreased Mir-155 and Mir-181a MicroRNA Expression, When Compared with Healthy Controls

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only